Inhibitory ligands on target cells

Inhibitory ligands on target cells refers to a broad functional category of cell-surface molecules that interact with inhibitory receptors on immune effector cells, such as Natural Killer (NK) cells and T lymphocytes, to suppress their activation [PubMed, 2021]. These ligands, which include Major Histocompatibility Complex (MHC) Class I molecules and checkpoint proteins like Programmed Death-Ligand 1 (PD-L1), are essential for maintaining peripheral tolerance and preventing autoimmune responses against healthy self tissues [NIH, 2023]. In the context of oncology, tumor cells frequently upregulate these ligands to exploit immune checkpoints, effectively creating an immunosuppressive shield that allows them to evade detection and destruction by the immune system [Nature Reviews Cancer, 2020]. Therapeutic strategies, such as the use of immune checkpoint inhibitors (e.g., Atezolizumab), aim to block these interactions to restore the anti-tumor activity of the host's immune system [FDA, 2022]. Because this term describes a functional group of diverse proteins rather than a single molecular entity, it is classified as a descriptive category rather than a specific canonical therapeutic target [UniProt].

Other names

Immune checkpoint ligandsNK cell inhibitory ligandsNegative regulatory ligandsMHC Class I moleculesSelf-ligands

These ligands bind to inhibitory receptors (such as PD-1, KIRs, or NKG2A) on immune effector cells, triggering the phosphorylation of Immunoreceptor Tyrosine-based Inhibitory Motifs (ITIMs) which recruit phosphatases to dampen activating signaling pathways [StatPearls, 2023].